LINC00467 and neoplasm: Targeting ASAP in patient-derived xenografts using CRISPR/Cas9 resulted in the inhibition of CRC cell proliferation and reduced tumor size, suggesting that targeting ASAP in CRC may be therapeutically beneficial.144